11 Jan 2019 Research

Myelofibrosis: Finding new ways to treat patients

Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.

Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.

Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.

The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.

Related posts

Leukaemia UK is looking for volunteers for their Patient Experience Advisory Panel

4 June 2022

Leukaemia UK is looking for volunteers for their Patient Experience Advisory Panel

Leukaemia UK is committed to championing advancements in better treatments and care for all. We want to ensure the needs of patients are at the heart of everything we do, and that the voices of people affected by leukaemia and related conditions are being heard. That is why we are setting up a Patient Experience Advisory Panel.

Leukaemia UK invests in next generation of blood cancer trial leaders

30 November 2023

Leukaemia UK invests in next generation of blood cancer trial leaders

This week, aspiring chief investigators of future cutting-edge blood cancer clinical trials took to Birmingham for the DIDACT Foundation’s inaugural Clinical Trials Workshop – an event funded by Leukaemia UK….

Clinical trial begins for pioneering new cancer treatment

10 January 2023

Clinical trial begins for pioneering new cancer treatment

Dr Konstantinos Tzelepis was awarded a Leukaemia UK research fellowship in 2020 and has developed a new class of cancer drug with the potential to treat leukaemia.

Leukaemia Care and Leukaemia UK announce financial support collaboration

19 August 2022

Leukaemia Care and Leukaemia UK announce financial support collaboration

Leukaemia Care and Leukaemia UK are pleased to announce a collaboration to provide financial support to people affected by leukaemia, through the financial hardship fund. Leukaemia Care have provided 364…